Date and Time: 10.00am – 17.00pm – 25th July 2013

9.30am – 15.15pm – 26th July 2013

Minutes: confirmed

Guideline Development Group Meeting  Tuberculosis
Place:  Orega Meeting Rooms
        3 Piccadilly Place
        Manchester

Present: Andrew Hayward (AH)(Chair)
Faizan Ahmed (FA)
Christine Bell (CB)
Ann Chapman (AC)
Timothy Collyns (TC)
Francis Drobniewski (FD) – 25th July 2013
Michael Eisenhut (ME)
Mango Hoto (MH)
Marc Lipman (ML) – 25th July 2013
Tessa Marshall (TM)
Philip Monk (PM)
Horace Reid (HR)

Apologies: Ibrahim Abubakar (IA)
Amy McConvill (AM)
Bertie Squire (BS)
Al Story (AS)
Marc Lipman (ML) – 26th July 2013
Francis Drobniewski (FD) – 26th July 2013

In attendance:

NICE Staff:

Emma Banks (EB)
Jenny Craven (JC)
Ben Doak (BD) – 25th July 2013
Chris Gibbons (CG)
Michael Heath (MH)
Rachel Kettle (RK)
Lucy Hoppe (LH)
Gabriel Rogers (GR) – 25th July 2013
Toni Tan (TT)

Notes
Notes

Day 1 – 25th July 2013

1. AH welcomed all to the fourth TB GDG meeting. Apologies were noted and the minutes of the last meeting were agreed as an accurate record of the previous meeting once a few minor corrections were made.

The Chair asked all GDG members to declare any relevant conflicts of interest. All in attendance at the meeting declared that they knew of no personal specific, personal non-specific, non-personal specific or non-personal non-specific interest in the development of this guideline that had not already been declared on appointment to the committee.

The Chair introduced the work to be presented and discussed over the next two days.

2. LH presented the evidence for the review questions which asked in people with active respiratory or non-respiratory TB do corticosteroids (as an adjunct to an anti-TB drug treatment regimen) decrease morbidity and morality compared with an anti-TB drug regimen alone? The GDG noted there were a good number of studies to discuss though the quality of those papers did range from very low to high. The group discussed all the evidence and went on to make some draft recommendations and research recommendations.

Day 2 – 26th July 2013

1. LH presented the review protocols for questions on the diagnosis and treatment of latent TB, co-morbidities & co-existing conditions and the diagnosis of active TB. The GDG discussed the inclusion and exclusion criteria for each question in turn and agreed the protocols.

2. There was no further matters of business arising.

Date, time and venue of the next meeting